In‐hospital outcomes of lacosamide versus levetiracetam for early adjunctive treatment of status epilepticus: A Nationwide Japanese retrospective cohort study
This study compared two intravenous antiseizure medications, levetiracetam (LEV) and lacosamide (LCM), as early add-on therapy for status epilepticus (SE), using data from a large Japanese inpatient database. The in-hospital mortality, length of hospital stay, or total medical costs did not differ significantly between the groups. However, patients treated with LCM had a lower chance of having a poor neurological status at discharge. While LEV is a well-established treatment for SE, this study suggests that LCM may be similarly effective and could offer an advantage, although more research is needed.
Authors
- Kiyohide Fushimi (ORCID: https://orcid.org/0000-0002-1894-0290)
- Yumiko Nakamura (ORCID: https://orcid.org/0000-0002-3440-1641)
- Masashi Hamada (ORCID: https://orcid.org/0000-0002-2866-8067)
- Shotaro Aso (ORCID: https://orcid.org/0000-0002-7804-2433)
- Satoshi Kodama (ORCID: https://orcid.org/0000-0002-0576-1859)
- Yuichiro Shirota
- Hiroki Matsui (ORCID: https://orcid.org/0000-0002-1049-7925)
- Hideo Yasunaga (ORCID: https://orcid.org/0000-0002-6017-469X)
- Tatsushi Toda
Institutions
- University of Iowa Hospitals and Clinics (US)
- National Center of Neurology and Psychiatry (JP)
- University of Tokyo Health Sciences (JP)
- Institute for Health Economics and Policy (JP)
- Department of Health (IE)
- Tokyo National Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Epilepsia Open
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1002/epi4.70182
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00